Roivant's Priovant Says FDA Approved LISRAYA For Dermatomyositis In Adults, First Targeted Therapy For The Disease; Available In U.S. Immediately
Share
Why It Matters
Roivant got permission from the FDA to sell a new medicine called LISRAYA that helps adults with a rare muscle disease. This is big because it's the first medicine specially made to treat this disease, which could help the company earn money and show their science works.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.